申万宏源证券晨会报告-20260213

Core Insights - The report highlights the innovative ADC technology platform of the company, focusing on its differentiated approach and extensive pipeline targeting various cancer types such as breast, lung, and prostate cancers [2][11] - The company has established multiple global partnerships for its innovative pipelines, advancing ADC+IO 2.0 combination therapies [11] - The report provides a buy rating for the company, projecting revenues of 1.632 billion, 1.555 billion, and 1.665 billion yuan for 2025-2027, primarily from product licensing income [3][11] Company Overview - The company is centered around a differentiated ADC technology platform, with four leading ADC technology platforms: DITAC, DIBAC, DIMAC, and DUPAC [2][11] - It has developed multiple core ADC pipelines targeting HER2, HER3, TROP2, and B7-H3, and is also working on next-generation products such as bispecific ADCs and immune ADCs [2][11] Pipeline and Collaborations - The company has secured significant global licensing agreements with major pharmaceutical companies, including BioNTech and GSK, with total transaction values exceeding 6 billion USD [11] - The DB-1311 (B7-H3 ADC) is noted for its broad indication coverage, with multiple data readouts expected in 2026 [3][11] Financial Projections - Revenue projections for the company are set at 1.632 billion yuan in 2025, 1.555 billion yuan in 2026, and 1.665 billion yuan in 2027, with anticipated net losses of 2.499 billion, 479 million, and 560 million yuan respectively [3][11] - A target price of 455.8 HKD is established, indicating a potential upside of 37% based on the DCF model [3][11] Future Development Focus - The company is focusing on building an innovative 2.0 pipeline, emphasizing the development of next-generation ADC products, including bispecific ADCs and immune ADCs [3][11] - The clinical development strategy is centered around the CP² approach, which integrates clinical development, platform, and pipeline [3][11]